5VM
5AM Venture Management Portfolio holdings
AUM
$260M
This Quarter Return
+12.14%
1 Year Return
+3.76%
3 Year Return
+144.87%
5 Year Return
+32.61%
10 Year Return
–
AUM
$377M
AUM Growth
+$377M
(+8.5%)
Cap. Flow
+$20.4M
Cap. Flow
% of AUM
5.4%
Top 10 Holdings %
Top 10 Hldgs %
73.32%
Holding
28
New
2
Increased
4
Reduced
2
Closed
3
Top Buys
| 1 |
Biohaven
BHVN
|
$17.1M |
| 2 |
Merus
MRUS
|
$14.3M |
| 3 |
Celldex Therapeutics
CLDX
|
$7.42M |
| 4 |
Pharvaris
PHVS
|
$5.89M |
| 5 |
Viridian Therapeutics
VRDN
|
$3.85M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$13.7M |
| 2 |
Disc Medicine
IRON
|
$8.33M |
| 3 |
Arvinas
ARVN
|
$6.28M |
| 4 |
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
|
$1.24M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
$639K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Enliven Therapeutics
ELVN
$1.2B
| $71.4M | 18.95% |
5,160,975
| – | – |
|
2
Entrada Therapeutics
TRDA
$208M
| $66.5M | 17.65% |
4,408,379
| – | – |
|
|
3
Pharvaris
PHVS
$1.39B
| $22.4M | 5.93% |
797,600
+210,000
| +36% | +$5.89M |
|
|
4
Celldex Therapeutics
CLDX
$1.47B
| $19.7M | 5.23% |
497,270
+187,000
| +60% | +$7.42M |
|
|
5
MoonLake Immunotherapeutics
MLTX
$3.54B
| $18.3M | 4.85% |
302,630
-10,580
| -3% | -$639K |
|
|
6
Biohaven
BHVN
$1.63B
| $17.1M | 4.54% |
+399,972
| New | +$17.1M |
|
|
7
Disc Medicine
IRON
$2.07B
| $17M | 4.51% |
294,221
-144,221
| -33% | -$8.33M |
|
8
Dianthus Therapeutics
DNTH
$759M
| $15.3M | 4.06% |
1,472,264
| – | – |
|
|
9
Merus
MRUS
$4.98B
| $14.3M | 3.8% |
+521,531
| New | +$14.3M |
|
10
Vor Biopharma
VOR
$250M
| $14.3M | 3.8% |
6,361,723
| – | – |
|
|
11
Viridian Therapeutics
VRDN
$1.5B
| $12.8M | 3.39% |
586,595
+176,595
| +43% | +$3.85M |
|
|
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $11.3M | 3% |
192,500
| – | – |
|
13
Viking Therapeutics
VKTX
$3.04B
| $10.9M | 2.89% |
585,000
| – | – |
|
14
Rallybio
RLYB
$22.4M
| $8.68M | 2.3% |
3,630,724
| – | – |
|
15
Tyra Biosciences
TYRA
$675M
| $7.69M | 2.04% |
554,979
+143,529
| +35% | +$1.99M |
|
16
AnaptysBio
ANAB
$569M
| $7.66M | 2.03% |
357,733
| – | – |
|
17
scPharmaceuticals
SCPH
$295M
| $7.53M | 2% |
1,200,647
| – | – |
|
18
Zentalis Pharmaceuticals
ZNTL
$122M
| $7.42M | 1.97% |
490,000
| – | – |
|
|
SPRB
19
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $6.93M | 1.84% |
2,364,000
| – | – |
|
20
Avidity Biosciences
RNA
$5.99B
| $6.02M | 1.6% |
665,555
| – | – |
|
21
Cogent Biosciences
COGT
$1.69B
| $4.65M | 1.23% |
790,440
| – | – |
|
22
Mersana Therapeutics
MRSN
$36.5M
| $3.03M | 0.8% |
1,305,000
| – | – |
|
23
Q32 Bio
QTTB
$20.9M
| $2.76M | 0.73% |
4,535,919
| – | – |
|
24
GH Research
GHRS
$837M
| $2.35M | 0.62% |
404,404
| – | – |
|
25
Cidara Therapeutics
CDTX
$1.66B
| $901K | 0.24% |
1,134,511
| – | – |
|